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Lys6or in NADPH-cytochrome P-450 reductase is modified by reductive alkylation with pyridoxal S-phosphate (pyridoxylation). Lysdo’ is protected 
against modification by the cosubstrate NADP(H). 
NADP(H) binding site; Lysine residue; Pyridoxal Y-phosphate; Micro sequencing; (Pig liver) 
1. INTRODUCTION 
According to the model proposed for the arrange- 
ment of the nucleotide binding sites in P450R, the 
NADP-PPi was tentatively assigned to the sequence 
Gly482-Arg5’8 showing homology to FAD-proteins 
[1,2]. However, this identification of the NADP-PPi 
site is not consistent with the following results: (i) the 
stretch Glys31-Va1536 present in all P450R with known 
structure [3,4] is related to a nucleotide 
(pyro)phosphoryl consensus sequence [2,5]; (ii) the 
P450R from yeast [3] shows insertions within the se- 
quence corresponding to Tyr476-Va1507 representing the 
predicted NADP-PPi site of mammalian P450R and 
(iii) the NADP(H)-protected Cys4’l and CY?~ [2,6] are 
located outside of this sequence [2]. To get further in- 
formation on the NADP(H) binding site, we identified 
the cosubstrate protected lysine(s) shown by differen- 
tial labelling [8,9]. 
DTNB, 0.1 M N&HCOs pH 8.2 until 3 mol TNB-/mol P450R were 
released. Reagents were removed on Sephadex G-25 equilibrated with 
0.1 M N&HCOs. To the eluate containing P450R, KCN was added 
up to 20 mM. After release of 3 mol TNB - /mol P45OR, the solution 
was loaded on Sephadex G-25 equilibrated with 0.1 M sodium borate 
pH 8.5 and eluted with this buffer. (ii) (CNbP450R (40-60 PM) was 
reacted with 1 mM PALP in 0.1 M sodium borate pH 8.5 for 15 min 
and then treated for a further 30 min after addition of NaCNBHp up 
to 0.1 M. Removal of reagents was achieved on Sephadex G-25 by 
elution with 0.1 M N&HC03 pH 8.2. 
2.3. Isolation of pyridoxylated peptides 
Digestion of the pyridoxylated (CNbP450R was performed with 
TPCK-trypsin ((CN)3PUOR:trypsin = 25:1 w/w) for 41 h at 37°C in 
0.1 M NH4HCO3 pH 8.2. Peptides were separated on HPLC column 
(0.46 cm x 25 cm) of Bakerbond Crs material (5 am; 33 nm) using 
a O-50% CHJCN gradient in 0.1% aqueous CFaCOOH (time of gra- 
dient: 60 min; 35°C; flow: 0.7 ml/min). Rechromatography was done 
on a Pharmacia Mino RPC SCrs/c~ (0.46 cm x 20 cm; 5 pm; 10 nm; 
12.5-50% CHaCN in 0.1% CFaCOOH; time of gradient: 60 min; 
35°C; flow: 0.7 ml/min). 
Sequencing was done with a Biosystems 477A sequencer equipped 
with a model 12OA on-line PTH analyzer. 
2. MATERIALS AND METHODS 3. RESULTS AND DISCUSSION 
2.1. Purification of P45OR 
Protease-solubilized P450R was isolated according to [lo]. En- 
zymatic activity was measured at 25°C according to [lo]. 
2.2. Modification of P45OR 
S-cyanylation and subsequent pyridoxylation of P450R was carried 
out at 25°C as follows: (i) P450R (40-60 PM) was reacted with 1 mM 
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Pyridoxylation was carried out with S-cyanylated 
P450R, since the reductive alkylation of proteins con- 
taining accessible cysteines like P450R is not specific 
for lysine residues. S-cyanylation at the three reactive 
cysteines of P450R (CYSTIC, CY?~ and CYST) was 
achieved as reported [7,11]. This modification did not 
adversely affect the P450R, since the specific activity of 
(CN)sP450R is about 5% higher than that of the un- 
modified enzyme. Therefore, the loss of activity caused 
by pyridoxylation of (CN)sP450R can be followed by 
NADPH-mediated cytochrome c reduction [ 1 I]. 
(CN)sP450R was strongly inactivated by pyridoxyla- 
tion under the conditions used (fig.1). In contrast, 
reductive alkylation with pyridoxal (1 mM) shows only 
a slight effect (fig. 1). In the presence of 3 mM NADP + 
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Fig.1. Modification of (CN)1P450R by reductive alkylation with 
PALP. 0, control; X, + 1 mM PALP; 0, + 1 mM PALP + 3 mM 
NADP + ; H, 1 mM PALP + 3 mM NADH; 0, 1 mM pyridoxal. 
(not NAD+) inactivation by pyridoxylation is not 
abolished but its rate is decreased by a factor of about 
5 (fig. 1). This incomplete protection by a cosubstrate is 
likely to be caused by a slow modification of ‘essential’ 
lysines outside the NADPH binding site. If any, 10% 
of the total flavin is lost by P450R during pyridoxyla- 
tion as determined by HPLC. To detect NADP(H)- 
protected lysine(s), (CNhP450R was pyridoxylated in 
the presence and absence of 3 mM NADP + for a 
period of 15 min (residual activity 85% and 20070, 
respectively) to avoid the reaction of lysines, whose 
reactivity is not dependent on the presence of 
cosubstrate. The HPLC map of the tryptic digest ob- 
tained from enzyme pyridoxylated in the presence of 
NADP + does not contain the main fluorescent peptide 
present in the HPLC map of the tryptic peptides from 
(CN)3P450R pyridoxylated in the absence of 
cosubstrate (fig.2). Edman degradation of this peptide 
revealed the sequence E-Q-P-Q-K601-V-Y-V-Q-H-L-L- 
K609. At step 5 of the Edman degradation no PTH- 
lysine is released. Amino acid analysis of the peptide by 
determination of the phenylthiocarbamoyl derivates 
showed a substance luted at a position typical for Ne- 
modified lysine. Cleavage of peptide Es9’-K609 with 
chymotrypsin led to one fluorescent subpeptide with 
the sequence E597-Y603. Consequently, Lys601 is the site 
of pyridoxylation protected by NADP + . 
This result confirms the conclusion based on the pro- 
tection of Cys4”and Cys 565 by the cosubstrate that 
stretches outside the predicted NADP(H) binding 
region are involved in the binding of cosubstrate. In 
ferredoxin-NADP + oxidoreductase (spinach), LYS*~~ is 
labelled by oxidized NADP + [ 121. This observation led 
to the suggestion that Lys601 of P45R located at a 
homologous position to that of LYS*~~ in the feredoxin- 
NADP + oxidoreductase is also participating in binding 
of NADP(H) [2,13]. Our studies confirm this proposal. 
A 
-1’ 
,’ 
,’ 
,’ 
, 
,,’ 
,I’ 
I’ 
,,’ 
/’ 
,I’ 
/’ 
I I I I I 
/’ 
,’ 
,,’ L.& ll I ,’ ,’ I’ 
13 /’ 
I’ 
/’ 
I 
100 
m 
E 
50 ) 
:: 
x 
m 
z 
50 g 
w 
0 
min 
Fig.2. HPLC map of tryptic peptides obtained from (CN)sP450R 
pyridoxylated in the absence (A) and the presence (B) of 3 mM 
NADP + . 
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